Regardless of rouble trouble.
Signs exclusive distribution agreement with Prima-Temp.
For the commercialisation of novel drug in Europe, Latin America and other markets.
As of 1 August.
Despite profit plunge.
Earnings report to be published this week.
Key drug to hit shelves in Western Europe soon.
500 employees to be sacked from the Gödöllő plant.
Operating profit margin also seen higher.
Leading pharma reports robust Q1 results.
Robust quarter projected.
18 billion forint investment at the door.
Magyar Telekom and OTP are the top picks.
'Buy' rating remains.
Profit doubled, yet share price is falling.
Analysts expect major profit growth for Q416.
Levosert goes to Europe.
In female healthcare product acquistions.
Negotiating the curves of the biosimilar scene.